SIA
United States
- Chicago, Illinois
- 16/12/2021
- Series B
- $15,000,000
Surgical Innovation Associates, Inc. (“SIA”, sia.health) is a commercial stage medical device company, committed to raising the standard of care in plastic, reconstructive, and general surgery and lowering systemic costs through “for surgeon, by surgeon” medical device innovation. Headquartered in downtown Chicago, Illinois, SIA’s proximity to academia and world-leading healthcare institutions has created the ideal ecosystem for the translation of concepts into devices to meet key clinical needs.
The company’s flagship product family, DuraSorb® Monofilament Mesh is on the market and indicated for use in reinforcement of soft tissues where weakness exists. DuraSorb® was specifically designed for plastic, reconstructive, and general surgery and is US FDA 510(k) cleared and CE marked. The product is available in multiple sizes, and is part of a growing pipeline of novel medical devices made from commonly-used resorbable polymers.
- Industry Biotechnology Research
- Website https://sia.health/
- LinkedIn https://www.linkedin.com/company/surgical-innovation-associates/
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)